戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 0001), insulin (51.7% vs 38.3%, P = 0.0341), anti-hypertensive (41.1% vs 26.0%, P < 0.0001), and chol
2                  ANP exhibits several potent anti-hypertensive actions in the kidney, adrenal gland a
3 or enzastaurin, and the clinically available anti-hypertensive agent hydralazine, both normalize aort
4             Since it was discovered that the anti-hypertensive agent ifenprodil has neuroprotective a
5 ars posttransplantation and increased use of anti-hypertensive agents, low-dose CsA was not associate
6 channel blockers (CCB) are widely prescribed anti-hypertensive agents.
7                   We show that the diuretic, anti-hypertensive, AMPA receptor modulator cyclothiazide
8 ric activity of AT(2)R is independent of its anti-hypertensive and anti-inflammatory effects.
9 xtract to proteolysis, leading to their high anti-hypertensive and antioxidant potentials.
10 , antifungal, anti-proliferative, antiviral, anti-hypertensive and immunomodulatory activities, sugge
11 evalence have corresponded with increases in anti-hypertensive and lipid-modifying drugs, respectivel
12 ted glomerular filtration rate, medications (anti-hypertensive and statin), LV mass index, and interi
13                   Antioxidant, antidiabetic, anti-hypertensive, and anticancer activities, lipid pero
14 se was estimated for lipid-modifying agents, anti-hypertensives, and anti-hyperglycemic medications.
15 therapeutics, anti-tumor drugs, antibiotics, anti-hypertensives, and anti-inflammatories.
16 therapeutics, anti-tumor drugs, antibiotics, anti-hypertensives, and anti-inflammatories.
17 s, such as hypolipidemic, anti-inflammatory, anti-hypertensive, anti-cancer, and hepatoprotective pro
18 ive peptides associated with ACE inhibitory, anti-hypertensive, anti-cancer, antimicrobial, antiviral
19 chidonic acid (AA) metabolism and tend to be anti-hypertensive, anti-inflammatory and protective agai
20 nal revascularization as an aid in improving anti-hypertensive control, preserving renal function, an
21               We observed sensitivity to the anti-hypertensive drug amiloride as well as modulation b
22  designed to test the effectiveness of three anti-hypertensive drug regimens and two levels of BP con
23                                    The three anti-hypertensive drug regimens include an angiotensin c
24 ne, a well tolerated, safe, centrally acting anti-hypertensive drug, could induce autophagy in cell c
25 ipine, an L-type calcium channel blocker and anti-hypertensive drug, induces autophagy and clears div
26                                           An anti-hypertensive drug, reserpine, suppressed TEV uptake
27 st olmesartan (Benicar(TM)), a highly potent anti-hypertensive drug.
28 ave been widely used in clinical settings as anti-hypertensive drugs and share a similar chemical sca
29                             Although several anti-hypertensive drugs have been developed as AT(1)R bl
30  target cardiovascular risk factors (such as anti-hypertensive drugs, anti-platelet agents and statin
31  range of organic anions including vitamins, anti-hypertensive drugs, anti-tumor drugs, and anti-infl
32  common and distinct binding modes for these anti-hypertensive drugs.
33  A (CsA) and also certain anti-epileptic and anti-hypertensive drugs.
34 bolism (anti-cholesterol), anti-diabetic and anti-hypertensive effects among others.
35 afferent renal nerves resulted in comparable anti-hypertensive effects to ablation of efferent and af
36 entration of specific peptides, particularly anti-hypertensives, from yogurt compared with their milk
37 nzyme (ACE) inhibitor enalapril, but not the anti-hypertensive hydralazine, decreased pulmonary neutr
38 nexpensive protein source of antioxidant and anti-hypertensive ingredient.
39 f excessive blood pressure and the number of anti-hypertensives into a combined score-the hypertensiv
40                  However, many adults are on anti-hypertensive medication (MEDS) which lowers their B
41 imated glomerular filtration rate, fat mass, anti-hypertensive medication and fasting glucose, (1) lo
42 termine the pre-intervention blood pressure, anti-hypertensive medication load and renal function, an
43 ithstood adjustment for demographic factors, anti-hypertensive medication use, history of diabetes, h
44                              Neither HDP nor anti-hypertensive medication were associated with attent
45 survival, routine achievement of steroid and anti-hypertensive medication withdrawal, gratifying incr
46 rity of hypertension (need for more than one anti-hypertensive medication) was also significantly low
47 populations will respond to certain types of anti-hypertensive medication.
48 t of hypertension and use of renoprotective, anti-hypertensive medication.
49 ised blood pressure and less likely to be on anti-hypertensive medication; they are 45% more likely t
50 vioural intervention to support adherence to anti-hypertensive medications and therefore to lower blo
51 t) infusion following a 2-week withdrawal of anti-hypertensive medications.
52 sfully transplanted patients were not taking anti-hypertensive medications.
53                            The prevalence of anti-hypertensive pharmacologic therapy was 4.2% (95% CI
54 and more studies are needed to elucidate the anti-hypertensive potential of oats.
55 CE more effectively, exhibiting the greatest anti-hypertensive potential, along with the presence of
56 lity checks of those peptides based on their anti-hypertensive potentialities.
57  polypeptides (3.4 kDa), which showed higher anti-hypertensive potentials (IC(50) = 0.30 and 0.27 mg
58                                              Anti-hypertensive requirement (32% TAC vs. 32% CsA) and
59                                    A maximal anti-hypertensive response of 33 +/- 5 mmHg was observed
60 ors with specific attention for obesity, and anti-hypertensive strategies, especially focused on life
61 mbotic, lipid-lowering, glucose-lowering and anti-hypertensive therapies, and exercise therapies that
62                              Despite current anti-hypertensive therapies, most individuals with hyper
63 effects of three medications used as initial anti-hypertensive therapy (ramipril, metoprolol, and aml
64  especially those not responding to standard anti-hypertensive therapy (resistant hypertension).
65  information and context on the intensity of anti-hypertensive therapy in conjunction with the releas
66 ety and efficacy of differing intensities of anti-hypertensive therapy in mild to moderate CKD, where
67                      Exclusion criteria were anti-hypertensive therapy, history of cardiovascular dis
68 nsive kidney disease who receive recommended anti-hypertensive therapy.
69 um (CAC) can further guide the allocation of anti-hypertensive treatment intensity.
70  years posttransplantation and required more anti-hypertensive treatment throughout the study period.
71 including from maternal smoking and maternal anti-hypertensive treatment.
72                                          All anti-hypertensive treatments have shown improvement in r
73                                          The anti-hypertensive, vasodilatory, anti-fibrotic, and anti
74 azide diuretics (TD) are commonly prescribed anti-hypertensives worldwide.